Depixus and Daiichi Sankyo to use MAGNATM technology to speed up the finding of RNA-targeted drugs
Depixus, a company specializing in interactomics, has partnered with Daiichi Sankyo to help speed up their RNA-targeted drug discovery program. They will be using Depixus' innovative MAGNA™ technology for this collaboration
MAGNA is a special technology that uses magnetic force spectroscopy. It can analyze dynamic biomolecular interactions in real time and with very high precision, down to the level of individual molecules. When it comes to RNA, we can learn a lot from studying how small molecules and proteins attach themselves to RNA structures in three dimensions. This helps us understand important details about how they bind, how quickly it happens, and how they work.
The team at Daiichi Sankyo will use MAGNA to study how lead molecules interact with various RNA targets that have not been revealed yet. This data will help with choosing the best hits and improving the leading candidates, which will make the company's RNA-targeted therapeutics pipeline progress faster and with less risk as they move towards clinical trials.
MAGNA is different from other analytical techniques. It doesn't give static snapshots or averaged bulk data. It also doesn't provide indirect measurements of molecular interactions. Instead, MAGNA gives direct readouts of dynamic binding and conformational changes. It does this by analyzing thousands of individual molecules. This tool is helpful for studying different types of molecular interactions. For instance, it can be used to examine how DNA, RNA, proteins, and small molecule therapeutics interact with each other. It has various applications in areas like discovering drugs that target RNA, understanding protein-protein interactions, developing PROTACs, and exploring molecular glues.
Gordon Hamilton, who is the CEO of Depixus and also a medical doctor, mentioned that the field of RNA-targeted therapeutics has a lot of potential but hasn't been fully explored yet. We are happy to work together with Daiichi Sankyo to use MAGNA in order to achieve our common goal of developing new medications for diseases that currently lack effective treatments.
Depixus is talking to other global pharmaceutical and biotech partners about working together. They want to study new targets and make new medicines faster. These medicines could change people's lives. The company is planning to release its MAGNATM One instrument in 2024. This instrument will bring the power of interactomics to academic and industrial laboratories. To learn more, you can visit the website www.depixus.com.
